White blood cell

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

Retrieved on: 
Monday, April 8, 2024
Find, White blood cell, AML, Patient, Acute myeloid leukemia, Cancer, AACR, Cryopreservation, Therapy, Pharmaceutical industry

“We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.

Key Points: 
  • “We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.
  • The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important innovation.
  • It has been previously thought that frozen samples could not be effectively thawed and used for cell viability assays.
  • While Notable will continue to evaluate and validate these sample handling methodologies, these data open the door to the use of cryopreserved samples from retrospective cohorts.

SBA Administrator Guzman Announces 17 New Women’s Business Centers

Retrieved on: 
Friday, March 29, 2024
Financial management, WBC, White blood cell, SBA, Master, MSI, Small business, Mentorship, Commerce, Male, Central business district, Senior counsel, Marketing, Human, Casino

“Under the Biden-Harris Administration, we have seen a historic Small Business Boom, with women, especially women of color, filing new business applications at double the rates of men,” said Administrator Guzman.

Key Points: 
  • “Under the Biden-Harris Administration, we have seen a historic Small Business Boom, with women, especially women of color, filing new business applications at double the rates of men,” said Administrator Guzman.
  • “The SBA’s expanding network of Women's Business Centers is meeting these new and established businesses where they are with resources to help them get funding to grow, create jobs, and strengthen our economy.
  • Through the SBA’s Office of Women’s Business Ownership (OWBO) , the 17 new WBCs – including 13 hosted by MSIs – will help diverse entrepreneurs pivot, grow, and navigate SBA resources they can use to ensure their businesses thrive.
  • “Through WBCs, the SBA provides practical help to women working hard to build successful businesses of their own,” said Christina Hale, Assistant Administrator for the Office of Women's Business Ownership .

SBA Unveils Updated Equity Action Plan to Advance the Biden-Harris Administration’s Commitment to Investing in Equity

Retrieved on: 
Wednesday, February 14, 2024
SAM, Small Business Administration, Health, Human, KEGG, SBLC, General Services Administration, SBA, GSA, Entrepreneurship, Small business, Management, Growth, White blood cell, Master, National Pan-Hellenic Council, Federal, Veteran, Community, American Jewish Committee, Negotiation, Partnership, Woman, Rural area, Commerce, Capital, Central business district, Face, MAS, Survivor, SDB, Government, Executive, Policy, SBIC

“The SBA’s updated Equity Action Plan recognizes the tremendous value that diverse entrepreneurs bring to our economy in terms of job creation, innovation, and domestic and international competition.

Key Points: 
  • “The SBA’s updated Equity Action Plan recognizes the tremendous value that diverse entrepreneurs bring to our economy in terms of job creation, innovation, and domestic and international competition.
  • Some SBA programs utilize a specific definition for underserved communities and/or disadvantaged small businesses as outlined in program statutes and regulations.
  • Improve Access to Disaster Assistance by modernizing technology, streamlining the application process, and increasing support for underserved disaster survivors navigating the application process.
  • The SBA’s regular engagement with the small business community and its stakeholders helped inform the Equity Action Plan .

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, December 7, 2023
Host, Food, ICU, Allergy, Hematology, Leukemia, FDA, AAD, Caregiver, Human services, Flow cytometry, MD, Infection, NLR, Administration, IGS, Granulocyte, White blood cell, WBC, Cell, Health, Sparrow Health System, Medical device, Sepsis, Research

MORRISVILLE, N.C., Dec. 7, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results that caregivers use to screen for health conditions including infection, leukemia, and other blood-related cancers, allergies, and many more.
  • Elevated levels of IGs have been shown to differentiate sepsis earlier than commonly used measures like lactate and procalcitonin1.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes that gained greater use during the pandemic.

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, November 16, 2023
Sepsis, Food, ICU, Allergy, Hematology, Leukemia, FDA, AAD, COVID-19, Flow cytometry, MD, Infection, NLR, IGS, Granulocyte, White blood cell, Innovation, WBC, Cell, Health, Sparrow Health System, Procalcitonin, Vaccine, Medical device, Research

MORRISVILLE, N.C., Nov. 16, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results to screen for health conditions including infection, leukemia and other blood-related cancers, allergies, and many more.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes, which gained greater use during the pandemic.
  • Sepsis, the body's extreme response to infection, is a life-threatening medical emergency that happens when infection triggers a chain reaction throughout the body.

Readout of SBA Administrator Guzman’s Visit to Togo, Meeting with Prime Minister Tomégah-Dogbé

Retrieved on: 
Wednesday, November 8, 2023
Female, Small business, Administrator, SSH, Face, Entrepreneurship, United, MCC, Interview, Growth, Partnership, Travel, Central business district, White blood cell, Woman, Forest Law Enforcement and Governance Program, SBA, Drug, African

During their meeting, Administrator Guzman and Prime Minister Tomégah-Dogbé discussed avenues to foster inclusive growth, including strategies to help more women and young people start businesses and enter regional and international trade.

Key Points: 
  • During their meeting, Administrator Guzman and Prime Minister Tomégah-Dogbé discussed avenues to foster inclusive growth, including strategies to help more women and young people start businesses and enter regional and international trade.
  • Following her meeting with Prime Minister Tomégah-Dogbé, Administrator Guzman visited an artesian village, where she met with local female small business owners and learned about their journey to small business ownership.
  • For follow-up interview requests for Administrator Guzman, please contact Rebecca
    Image Description: SBA Administrator Isabel Casillas Guzman (L) meets with local entrepreneurs in Lomé.
  • Image Description: SBA Administrator Isabel Casillas Guzman (L) speaks with press after the MCC Threshold Program reception in Lomé.

SBA Administrator Guzman Celebrates Anniversary of Women’s Business Ownership Act, Announces FY23 Lending to Women-Owned Businesses

Retrieved on: 
Wednesday, October 25, 2023
Women's Business Ownership Act, Small business, Senior counsel, Human, Legislation, Male, Economic policy of the Joe Biden administration, Business, The Business Council, Central business district, White blood cell, Woman, SBA, Bank

5050) by announcing new data showing SBA-backed loans to women-owned small businesses are up nearly 70 percent under the Biden-Harris Administration, totaling $5.1 billion in lending to women-owned businesses in FY23.

Key Points: 
  • 5050) by announcing new data showing SBA-backed loans to women-owned small businesses are up nearly 70 percent under the Biden-Harris Administration, totaling $5.1 billion in lending to women-owned businesses in FY23.
  • The Women's Business Ownership Act of 1988 helped change the way women do business in America – most importantly by empowering them to start up on their own.
  • “SBA’s reforms to its lending programs are delivering on this commitment, as new SBA data shows there has been a 70 percent increase in SBA lending to women-owned businesses under this administration.
  • Majority women-owned businesses now make up more than one-fifth of the SBA’s lending portfolio, compared to 15.6 percent in FY20.

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Retrieved on: 
Wednesday, October 25, 2023
Bone pain, Research, Plasma, Clinical trial, AAV, DBS, Biomarker, AST, Congress, Liver, Cancer Treatment Centers of America, CEST, Cell, Enzyme replacement therapy, White blood cell, Tissue, Gene, Glucocerebrosidase, Blood, ESGCT, Gaucher's disease, Safety, European Society for Primary Immunodeficiencies, Lysosome, ALT, Pharmaceutical industry, Patient

LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, show a substantial reduction of glucosylsphingosine (lyso-Gb1) levels in the blood of the first patient treated with FLT201. Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes. These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.

Key Points: 
  • Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes.
  • These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.
  • Reduction in lyso-Gb1 in the blood is strongly correlated with improvement in clinical outcomes in Gaucher disease.
  • The presentation entitled “Results from GALILEO-1, a First-In-Human Clinical Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1” is part of a session taking place from 14:30-16:30 CEST (8:30-10:30 a.m.

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Retrieved on: 
Wednesday, October 4, 2023
Gaucher's disease, Half-life, First grade, Cell, Bone pain, AAV, Plasma, Patient, White blood cell, ALT, Liver, Enzyme replacement therapy, Therapy, AST, Study, White, Safety, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Glucocerebrosidase

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitating genetic disorder in which a deficiency of the GCase enzyme leads to a buildup of harmful substrates, causing symptoms including enlarged spleen and liver, low blood counts, bone pain and reduced lung function. In addition to demonstrating a favorable safety and tolerability profile, data from the first two patients in GALILEO-1 show that a single infusion of FLT201 led to several hundred-fold increases in GCase activity in plasma and normalization of GCase activity in leukocytes.

Key Points: 
  • ET
    LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease.
  • "These initial clinical data are very compelling,” said Pilar Giraldo, M.D., Ph.D., hematologist at the Spanish Foundation for the Study and Therapy of Gaucher Disease, Quirónsalud Hospital – Zaragoza, and an investigator in the GALILEO-1 trial.
  • “While existing therapies have had a significant impact on the disease, many patients continue to experience symptoms and current therapies come with a heavy lifelong treatment burden.
  • ET today to discuss these initial clinical data for FLT201 in Gaucher disease.

Readout on SBA Administrator Isabella Casillas Guzman’s Appearance at SBDC Annual Conference

Retrieved on: 
Monday, September 11, 2023
Linda, Small business, Florida Small Business Development Center Network, Interview, Central business district, Senior counsel, Annual, AAPI, Investment, Tees Rowing Club, White blood cell, SBA, Growth, SCORE, Renewable energy

NASHVILLE, Sept. 11, 2023 (GLOBE NEWSWIRE) -- On Wednesday, September 6, U.S. Small Business Administrator Isabella Casillas Guzman traveled to Nashville, Tennessee, for the Annual America’s Small Business Development Centers (SBDC) 44th annual conference.

Key Points: 
  • NASHVILLE, Sept. 11, 2023 (GLOBE NEWSWIRE) -- On Wednesday, September 6, U.S. Small Business Administrator Isabella Casillas Guzman traveled to Nashville, Tennessee, for the Annual America’s Small Business Development Centers (SBDC) 44th annual conference.
  • The SBA administers the network of Small Business Development Centers which provide entrepreneurs with counseling, training, and resources to help small business communities thrive throughout the country.
  • She also discussed how President Biden’s Investing in America agenda is delivering record-low unemployment rates, a small business boom, and soaring job creation.
  • America’s SBDCs offer in-depth courses and networking opportunities, many geared toward underserved communities including Black, Hispanic, AAPI, veteran, woman, and rural small business owners.